Organon & Co.

AI Score

0

Unlock

15.84
0.18 (1.15%)
At close: Jan 14, 2025, 3:59 PM
15.81
-0.16%
After-hours Jan 14, 2025, 04:10 PM EST
undefined%
Bid 15.74
Market Cap 4.08B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 5.05
PE Ratio (ttm) 3.14
Forward PE n/a
Analyst Sell
Ask 15.95
Volume 1,689,289
Avg. Volume (20D) 3,404,636
Open 15.79
Previous Close 15.66
Day's Range 15.73 - 16.05
52-Week Range 13.87 - 23.10
Beta undefined

About OGN

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology pr...

Sector Healthcare
IPO Date May 14, 2021
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN

Analyst Forecast

According to 3 analyst ratings, the average rating for OGN stock is "Sell." The 12-month stock price forecast is $20, which is an increase of 26.30% from the latest price.

Buy 33.33%
Hold 33.33%
Sell 33.33%
Stock Forecasts

Next Earnings Release

Organon & Co. is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $1.59B, reflecting a -0.5% YoY shrinking and earnings per share of 1.03, making a 17.05% increase YoY.
2 months ago · Source
-2.72%
Organon & Co shares are trading lower after the FD... Unlock content with Pro Subscription
11 months ago · Source
+13.81%
Organon shares are trading higher after the company reported better than expected Q4 2023 earnings and issued 2024 guidance.